Screener
Dianthus Therapeutics DNTH Total Revenue
Total Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Dianthus Therapeutics’s 10-Q, filed November 5, 2025.
- Filed
- Nov 5, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-266920
| Line item | Three Months Ended September 30, 2025 | Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 |
|---|---|---|---|---|
| Revenues: | ||||
| License revenue - former related party | — | $2,172 | — | $4,909 |
| License revenue | 396 | — | 1,752 | — |
| Total revenues | 396 | 2,172 | 1,752 | 4,909 |
| Operating expenses: | ||||
| Research and development | 32,489 | 25,544 | 85,743 | 56,692 |
| General and administrative | 8,195 | 6,528 | 24,401 | 18,165 |
| Total operating expenses | 40,684 | 32,072 | 110,144 | 74,857 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's total revenue?
- Dianthus Therapeutics (DNTH) reported total revenue of $396K in Q3 2025.
- How has Dianthus Therapeutics's total revenue changed year-over-year?
- Dianthus Therapeutics's total revenue decreased by 81.8% year-over-year, from $2.17M to $396K.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Dianthus Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude